Winflunin (Vinfluninum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Antitumor agents of vegetable origin

Included in the formulation
  • Javlor
    concentrate d / infusion 
    Pierre Fabre Medication Production     France
    • АТХ:

    L.01.C.A.05   Winflunin

    Pharmacodynamics:An alkaloid of vegetable origin, a derivative of vinca alkaloid, has a cytostatic antimitotic effect. By binding to tubulin, it inhibits the polymerization of microtubule proteins of cellular cytoplasm, disrupting the dynamic equilibrium of the polymerization-depolymerization process, which ensures the functioning of intracellular structures throughout the cell life cycle, which leads to apoptotic cell death as a result of prolonged blockage of mitosis.

    Pharmacokinetics:After intravenous administration, the bond with plasma proteins is 68%.

    Metabolism in the liver with the formation of the active metabolite 4-O-deacetylvinvlunine.

    The half-life is 40 hours, 4-O-deacetylvinvinlunine 120 hours.

    Elimination by the kidneys.

    Indications:

    It is used for monotherapy of patients with locally advanced or metastatic urothelial transitional cell carcinoma with a negative effect from therapy with platinum drugs.

    ICD-10

    II.C64-C68.C67   Malignant neoplasm of bladder

    II.C64-C68.C64   Malignant neoplasm of kidney, except for renal pelvis

    II.C64-C68.C65   Malignant neoplasm of renal pelvis

    II.C64-C68.C66   Malignant neoplasm of ureter

    II.C64-C68.C68.0   Malignant neoplasm of urethra

    Contraindications:Postponed infectious diseases 2 weeks before the start of treatment, severe hepatic and renal failure, individual intolerance, children under 18 years of age.

    Carefully:

    Heart failure, bradycardia, electrolyte imbalance (hypokalemia, hypomagnesemia), renal and hepatic insufficiency of moderate degree, hypersensitivity.

    Pregnancy and lactation:

    Recommendations for FDA - category X. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Intravenously slowly for 20 minutes, 320 mg / m2 every 3 of the week.

    The highest daily dose: 320 mg / m2.

    The highest single dose: 320 mg / m2.

    Side effects:

    Central and peripheral nervous system: headache, depression, insomnia, peripheral neuropathy, demyelinating polyneuropathy, lethargy.

    Respiratory system: shortness of breath, cough, rhinorrhea, epistaxis, pneumonia.

    Hemopoietic system: neutropenia, thrombocytopenia, lymphopenia

    The cardiovascular system: tachycardia, "hot flashes", rarely - thromboses, ischemia of the heart muscle, myocardial infarction.

    Digestive system: nausea, vomiting, diarrhea, stomatitis, abdominal pain, candidiasis of the oral cavity, bloating.

    Musculoskeletal system: myalgia, arthralgia, muscle weakness.

    Dermatological reactions: alopecia, nail damage, hyperhidrosis, palmar-plantar erythrodysesthesia, erythema.

    Sense organs: conjunctivitis, increased lacrimation, pain in the ears, visual disturbances.

    Allergic reactions.

    Overdose:Increased side effects.

    Treatment is symptomatic.

    Interaction:

    With simultaneous admission with carbamazepine, St. John's wort, rifampicin, phenytoin, the concentration of vinflunin in the blood plasma decreases.

    Simultaneous use with opioids increases the risk of constipation.

    Special instructions:

    Women of the reproductive period during treatment with vinflunin is recommended to use reliable contraceptive methods during the drug intake and within three months after its termination.

    In the treatment it is not recommended to drive vehicles and work with moving mechanisms.

    Instructions
    Up